Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Here is how CRISPR Therapeutics AG (CRSP) and Applied Molecular Transport Inc. (AMTI) have performed compared to their sector so far this year.

Has CRISPR Therapeutics (CRSP) Outpaced Other Medical Stocks This Year?

CRISPR Therapeutics' (CRSP) fourth-quarter 2022 loss is narrower than expected, while sales miss estimates.

CRISPR (CRSP) Q4 Earnings Surpass Estimates, Sales Miss

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 39.22% and 99.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Misses Revenue Estimates

-Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in Europe for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD); U.S. rolling Biologics Licensing Application (BLA) submission on track for completion by end of Q1 2023-

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Ginkgo Bioworks Holdings

Both are on the verge of fast growth, and they haven't had any major setbacks yet.

2 Bruised Growth Stocks to Buy While They're Cheap

NextEra Energy

These two companies are on track to flourish through the end of the decade.

2 Marvelous Growth Stocks to Buy Today and Hold for 5 Years or Longer

If approved, CRISPR's first product may deliver blockbuster sales.

Beat the Dow Jones With CRISPR Therapeutics Stock

Editas Medicine

They're both at the cutting edge of gene-editing technology.

These 2 Biotech Stocks Could Soar in the Next Bull Market

CRISPR Therapeutics AG (NASDAQ:CRSP ) SVB Securities Global Biopharma Conference Call February 15, 2023 1:40 PM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Mani Foroohar - SVB Securities Mani Foroohar Good afternoon and good morning to those still on the West Coast. Welcome to this next session of our Annual Global Biopharma Conference here at SVB Securities.

CRISPR Therapeutics AG (CRSP) SVB Securities Global Biopharma Conference (Transcript)

BioMarin Pharmaceutical

Sight Sciences

These three companies are attractive targets for their potential.

3 Prime Healthcare Takeover Targets

Amazon

Alphabet

Vertex Pharmaceuticals

The time is right for each of these great stocks.

The Best Stocks To Invest $5,000 in Right Now

Etsy

Novavax

All of these players are cheap today considering their growth potential.

These Cheap Growth Stocks Could Supercharge Your Portfolio

Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals.

Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals?

CRISPR shares are ripe for a rebound after dropping 46% last year.

Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen.

CRISPR Therapeutics shares had a rough 2022, but the stock might soon surge back.

Ready to Buy the Dip? Consider This Gene Editing Stock

ARK Innovation ETF

Intellia Therapeutics

Cathie Wood is bullish about these stocks. And so are Wall Street analysts.

3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%

Moderna

Inmode Ltd

These stocks all fell by double digits last year.

3 No-Brainer Growth Stocks to Buy in 2023

CRISPR Therapeutics AG (CRSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Strength Seen in CRISPR Therapeutics AG (CRSP): Can Its 7.2% Jump Turn into More Strength?

10X Genomics

CRISPR is an acronym which refers to a series of DNA sequences in bacteria and other organisms. Scientists have begun editing genes, including CRISPR,  to try to improve human health.

3 CRISPR Stocks to Buy Now Or You'll Be Kicking Yourself Later

Beam Therapeutics

Cellectis SA

Sangamo Therapeutics

Verve Therapeutics

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.

7 CRISPR Stocks With the Best Long-Term Potential

AbbVie

To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive.

3 Gene Editing Stocks to Buy Now OR You'll Be Kicking Yourself Later

Global X Genomics & Biotechnology ETF

Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe.

3 Gene Editing Stocks With the Best Long-Term Potential

bluebird bio

Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.

Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?

Coinbase

DraftKings

Exact Sciences

Invitae

Pacific Biosciences of California

Roblox

Roku

Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.

Cathie Wood Is Crushing It This Year Thanks To 9 Stocks

CureVac B.V

Exelixis

Incyte

Pfizer

Sarepta Therapeutics

If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster.

7 Biotech Stocks That Will Make You Rich in 10 Years

News for CRISPR Therapeutics Stock (CRSP)